BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma
This secondary analysis of the GHSG HD21 randomized clinical trial evaluates the tolerability and impact of BrECADD vs escalated BEACOPP on health-related quality of life for patients with Hodgkin lymphoma.
Authors
- Justin Ferdinandus (ORCID: https://orcid.org/0000-0002-3481-7997)
- Sebastian Scholl (ORCID: https://orcid.org/0000-0003-2893-3630)
- Janina Jablonski
- Yon-Dschun Ko
- Horst Müller
- Wolfram Jung
- Andreas Rank
- Roland Schroers
- Karolin Behringer
- V. Diehl
- Vladan Vucinic
- Gundolf Schneider
- Andrea Kerkhoff
- Michael Fuchs
- Max S. Topp
- Peter Borchmann
Institutions
- University of Cologne (DE)
- University Hospital Augsburg (DE)
- Düsseldorf University Hospital (DE)
- University Hospital Münster (DE)
- German Inflammatory Bowel Diseases Study Group (DE)
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
- Universitätsmedizin Göttingen (DE)
- Universitätsklinikum Würzburg (DE)
- Jena University Hospital (DE)
- Johanniter-Krankenhaus Bonn (DE)
- University Hospital Cologne (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1001/jamaoncol.2025.6327
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00